Entero Therapeutics Goodwill

The latest goodwill for ENTO is $14M as of June 2026. That compares with $1.7M in the prior-year period — up 734.1% year over year. Investors often review this figure alongside Entero Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ENTO's goodwill moved from $1.7M to $14M — a 734.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Entero Therapeutics's operating scale or balance-sheet position.

A goodwill figure of $14M for ENTO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ENTO's goodwill ($14M), review year-over-year change from $1.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.